As shown in Figure 6 (SKOV3) and in Supplementary Figure S8 (LS174T), up-regulation of the epithelial markers claudin-2 and E-cadherin and down-modulation of the mesenchymal markers vimentin and fibronectin were clearly achieved when cells were incubated with ST8176AA1, but little if any effect was obtained with trastuzumab, thus confirming the ability of ST8176AA1 to counteract EMT of tumor cells clearly dependent on epigenetic modulation through the release of the active HDAC inhibitor. This evidence concerns the gene CLDN2 and neoplasm.